BioDiem testing BDM-I in schistosomiasis
11 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and the QIMR are moving to proof-of-concept testing of BioDiem’s antimicrobial in the parasitic worms that cause the major tropical disease schistosomiasis.
Cellmid options cancer diagnostics tech
11 February, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) has secured an option agreement with Japan’s Fujikura covering its midkine cancer diagnostics technology in latex-based tests.
Bioniche details plans for Urocidin
11 February, 2013 by Dylan Bushell-EmblingIn a letter to shareholders, Bioniche’s (ASX:BNC) CEO has laid out some plans for the future of bladder cancer treatment Urocidin following its split with former commercialisation partner Endo Pharmaceuticals.
Phosphagenics solves oxycodone patch design problems and plans for new trial
11 February, 2013 by Tim DeanPhosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter.
Free directory listing for Australian biotech and medtech companies
07 February, 2013 by AusBiotechAusBiotech manages two national directories and invites all Australian biotechnology and medical technology companies to list free of charge.
Mesoblast up following patents in US and China
07 February, 2013 by Tim DeanMesoblast (ASX:MSB) has made gains on the ASX following an announcement it has secured further patents covering its technology in the US and China.
Cynata’s stem cells show promise in treating critical limb ischemia
06 February, 2013 by Tim DeanAn animal trial has shown Cynata’s mesenchymoangioblasts (MCA) cells can help improve blood flow in mice with induced critical limb ischemia.
Allied finds CardioCel better at seeding stem cells
06 February, 2013 by Dylan Bushell-EmblingTests of tissue engineered by Allied Healthcare’s (ASX:AHZ) ADAPT technology support its ability to be used for a “truly regenerative treatment”, according to its CEO.
Cochlear record revenue fails to impress investors
06 February, 2013 by Tim DeanCochlear (ASX:COH) has posted record revenue for the second half of 2012, with sales up 27%, although the share price tumbled over 9% following the news.
Metabolic eyes human trials for experimental osteoarthritis treatment
06 February, 2013 by Tim DeanA positive result from an animal trial of Calzada (ASX:CZD) subsidiary Metabolic Pharmaceuticals’ osteoarthritis treatment could lead to phase II human trials beginning soon.
TGA consults on proposed changes to pre-market assessment for medical devices
05 February, 2013 by AusBiotechThe Therapeutic Goods Administration has proposed changes to the pre-market assessment requirements in its consultation paper released in January.
BioDiem expanding indications for BDM-I
04 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) is extending a research agreement with US-based NIAID to cover the evaluation of antimicrobial BDM-I in tuberculosis and serious fungal infections.
Alchemia progresses with colorectal cancer trial
04 February, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has enrolled the 390th patient for its phase III trial of HA-Irinotecan in metastatic colorectal cancer and expects to reach the primary endpoint in early 2014.
PolyNovo to file with FDA to seek NovoSorb in US
04 February, 2013 by Tim DeanCalzada (ASX:CZD) subsidiary PolyNovo will seek marketing approval in the US for NovoSorb, its dressing for hard-to-heal pressure sores.
Pharmaxis stock plummets on negative FDA recommendation
31 January, 2013 by Tim DeanPharmaxis (ASX:PXS) stock has dropped 40% following a negative recommendation from an expert panel that Bronchitol should be approved by the FDA.
